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Abstract
Distant metastases of human breast cancers have been suggested to be more different from each other than from
their respective primary tumors, based on expression profiling. The mechanism behind this lack of similarity be-
tween individual metastases is not known. We used cDNA microarrays to determine the expression profiles of
pulmonary metastases and primary mammary tumors in two distinct transgenic models expressing either the
Neu or the Wnt-1 oncogene from the mouse mammary tumor virus long terminal repeat (MMTV LTR). We found
that pulmonary metastases are similar to each other and to their primary tumors within the same line. However,
metastases arising in one transgenic mouse line are very different from either metastases or primary tumors aris-
ing in the other line. In addition, we found that, like their primary tumors, lung metastases inWnt-1 transgenic mice
harbor both epithelial and myoepithelial tumor cells and cells that express the putative progenitor cell marker ker-
atin 6. Our data suggest that both gene expression profiles and cellular heterogeneity are preserved after breast
cancer has spread to distant sites, and that metastases are similar to each other when their primary tumors were
induced by the same oncogene and from the same subset of mammary cells.
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Introduction
Breast cancer evolves from atypical ductal hyperplasia, to carcinoma
in situ, then invasive carcinoma, and finally distant metastasis, which
is usually the cause of death [1,2]. Expression array studies of a small
number of human breast cancer metastases found that they were
more similar to their corresponding primary tumors than to each
other [3–6]. These results have been interpreted to suggest that ex-
pression profiles do not change significantly in the progression from
primary lesions to distant metastases [7].
However, it is not clear why metastases are less similar to each other,
especially because the local environment in the metastasis sites might
induce a common set of genes in all of the metastases in question
[4,8]. Because only a small number of paired samples have been an-
alyzed, it is possible that the dissimilarity may have been caused by
heterogeneity in causal mutations, differentiation stages of the cancer-
originating cell, or genetic backgrounds, all of which have been re-
ported to have an influence on gene expression patterns [7,9,10]
(Bu et al., unpublished data).
Would the expression profiles of metastases still be more similar
to those of their primary tumors than to each other, if the compar-
ison could be made between tumors that were induced by the same
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oncogenic mutation from the same type of cell? Mouse models have
the advantage of purer genetic background, known initiating genetic
alterations, and better controlled cell of origin through the use of cell
type–specific transgenic promoters; they have been widely used to
provide insights in human cancer evolution [11]. In this report, we
investigated these issues by comparing expression profiles and cellular
composition of distant metastases and primary tumors in two distinct
mouse models that express the Wnt or the Neu oncogene.
Materials and Methods
Tissue Samples
The MMTV-Neu transgenic mouse line (on the FVB background)
carries a rat cDNA encoding the wild-type Neu (ErbB2/HER2) pro-
tein [12]. MMTV-Wnt-1 transgenic mice [13] were on a mixture of
FVB (>75%), SJL, and C57BL/6 strains. Metastases used in the
study were gross metastases dissected from lung tissues using scalpels.
They included four from MMTV-Wnt-1 transgenic mice that were
bearing a primary tumor or had had one primary tumor removed by
survival surgery, six experimental metastases induced by injecting pri-
mary mammary tumor cells from MMTV-Wnt-1 transgenic mice
into the tail vein of the same mice, three spontaneous metastases from
tumor-bearing MMTV-Neu transgenic mice, and two experimental
metastases induced by injecting primary MMTV-Neu–induced mam-
mary tumor cells into the tail vein of nontransgenic mice. The 35 pri-
mary tumors—23 and 12 from MMTV-Wnt-1 and MMTV-Neu
transgenic mice, respectively—have been described [14]. All tissue
samples were snap-frozen in liquid nitrogen and kept at −80°C before
use. After being ground into fine powder in liquid nitrogen, these tis-
sues were subject to RNA extraction using Trizol (Invitrogen, Carlsbad,
CA). The reference RNA was a mixture of ovarian RNA (cat no. 7824;
Ambion, Austin, TX) and RNA extracted from tissues of liver, spleen,
kidney, thymus, pancreas, lung, and normal lactating mammary gland
of FVB mice of 6 months of age. All reference RNA used in this study
and in our previous study [14] were from a single preparation, snap-
frozen as aliquots (for single use), and stored at −80°C.
cDNA Microarray Hybridization, Data Extraction,
and Statistical Analysis
All arrays used in this report were generated using the same batch
of array prints (mouse 15k cDNA arrays, printed at the National
Cancer Institute Microarray Facility) described previously [14]. La-
beling, hybridization, scanning, and microarray analyses were per-
formed for the 15 metastasis samples and the 35 primary tumors
at the same time and as previously described [14]. The data for these
primary tumors have been described in our previous report [14] and
deposited into the Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/geo/) under the series number
GSE2860. The 15 new arrays of pulmonary metastases have been
deposited into the GEO database under the same series number.
Microarray images were analyzed and normalized to generate log-
arithmic ratios of test-to-reference. Corresponding quality measure-
ments in each experiment were calculated using the ArraySuite
software based on the Scanalytics IPlab platform (Scanalytics, Fairfax,
VA) and as described [15]. Arrays of poor quality were excluded from
further analysis. Genes with a low average quality (<0.5) across all
arrays were excluded from subsequent data analyses. Unsupervised
average linkage hierarchical clustering analysis and multidimensional
scaling (MDS) analysis were performed as described [14] to assess the
relationship among different sample groups. A two-sample permuta-
tion t test, as described previously [14], was used to identify genes that
were significantly different between two groups of samples (P < .001).
Immunohistochemical Staining
Tissues were freshly collected, fixed in 10% neutral formalin over-
night, and processed as previously described [16] to obtain paraffin sec-
tions of 4 μm thickness. Immunohistochemical staining was performed
using Vector ABC kits and the Nova-Red substrate (Vector Laborato-
ries, Burlingame, CA) following the manufacturer’s recommendations
and as described [14]. Primary antibodies used include rabbit IgGs
against keratin 6 (Covance, Philadelphia, PA), mouse monoclonal anti-
bodies against α-smooth muscle actin (α-SMA; Dako, Philadelphia, PA),
and rat anti–keratin 8 [17,18].
Results
Comparing Metastases and Primary Tumors in Either the
MMTV-Neu or the MMTV-Wnt-1 Model
Neu (HER2/ErbB2) encodes a member of the epidermal growth
factor receptor family of receptor tyrosine kinases [19], and is ampli-
fied in approximately 25% of human breast cancers [20]. Transgenic
mice (MMTV-Neu) expressing Neu from the promoter in the mouse
mammary tumor virus long terminal repeat (MMTV LTR), which is
active primarily in more differentiated mammary epithelial cells as
well as in some undefined mammary progenitor cells [21–23], de-
velop mammary tumors at a median age of 7 months [12]. Micro-
scopic lesions are detected in the lung in 75% of cases, but gross
metastases are rare [12]. Members of the Wnt gene family encode
an extracellular protein that binds to membrane coreceptors Frizzled
and low-density lipoprotein receptor–related protein (LRP) 5/6,
leading to stabilization of β-catenin and activation of the mammalian
target of rapamycin (mTOR) pathway [24,25]. Wnt signaling is im-
plicated in tumorigenesis of the breast and many other tissue types
[25]. MMTV-Wnt-1 transgenic mice develop mammary tumors with
a median latency of six months [13]. Microscopic lung metastases are
found in approximately 35% of tumor-bearing mice on euthanasia
(Podsypanina, unpublished data). Gross metastases are infrequent as
in MMTV-Neu transgenic mice, but can be enhanced after removal
of the primary lesion through survival surgery [13] (Podsypanina, un-
published data).
One of the major obstacles in profiling metastatic tumors is ob-
taining sufficient amounts of tumor samples for RNA extraction.
In this study, we examined a large cohort of mice and/or employed
survival surgery to remove the initial primary tumor to enhance the
growth of metastases (see Material and Methods section for detail).
We were able to collect three spontaneous pulmonary metastases
from MMTV-Neu transgenic mice, and four pulmonary metastases
from MMTV-Wnt-1 transgenic mice through survival surgery to re-
move primary tumors. In addition, we generated two and six exper-
imental metastases from tail vein injection of cell suspensions made
from primary tumors from MMTV-Neu and MMTV-Wnt-1 trans-
genic mice, respectively.
Using mouse 15k cDNA arrays, we determined the expression
profiles of these metastases (5 from MMTV-Neu transgenic mice
and 10 from MMTV-Wnt-1 transgenic mice) and their primary tu-
mors in both models (12 from MMTV-Neu transgenic mice and 23
from MMTV-Wnt-1 transgenic mice). Using unsupervised average
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linkage hierarchical clustering analysis and MDS [14] to analyze
these arrays, we identified two main clusters: one comprises metasta-
ses and primary tumors from MMTV-Neu transgenic mice, and the
other contains metastases and primary tumors from MMTV-Wnt-1
transgenic mice (Figure 1A and data not shown).
This segregation based on the model may not be surprising, since
besides the initiating oncogene, these two models are also different in
histopathologic features, cellular composition, estrogen receptor (ER)
status, and possibly the cell of origin—whereas tumors in the
MMTV-Neu model appear to arise from more differentiated mam-
mary epithelial cells, lack histologic differentiation or ER expression,
and contain predominantly epithelial tumor cells; tumors arising in
MMTV-Wnt-1 transgenic mice appear to arise from progenitor cells,
display a more differentiated histopathology, are usually ER+, and
harbor mixed cell lineages including epithelial cells, myoepithelial
cells, and cells that express markers (Sca-1, keratin 6, and CD24/
CD29) putatively associated with progenitor cells [18,26–31]. In ad-
dition, cyclin D1 is required for carcinogenesis in the MMTV-Neu
model, but is dispensable in the MMTV-Wnt-1 model [32]. Further-
more, there is a slight difference in the genetic background between
these two models.
To determine whether eliminating the genes associated with these
other differences might change the dendrogram structure and reveal
similarities between metastases in the two models, we filtered the
1296 genes that we have reported to be differentially expressed be-
tween primary tumors in these two models (P < .001) [14], and an
additional 1162 genes that had a P value between .001 and .05 to
ensure a more stringent analysis. Of the remaining 12,361 genes,
6657 genes were excluded for either low quality or near identical ex-
pression across all the samples. In the end, 5704 genes were included
for hierarchical clustering and MDS analyses. Again, the two models
separated into two clusters, with the metastases grouping with pri-
mary tumors in each model (Figure 1, B and C ).
Within the MMTV-Neu transgenic model, the expression profiles of
the metastases were highly similar to each other, and also to those of
the primary tumors (Figure 1). In accord, 96% of the genes (1207
of 1263) that we have previously identified as differentially expressed
between primary tumors from MMTV-Neu transgenic mice and vir-
gin mammary glands from nontransgenic mice [14] were not signif-
icantly differentially expressed between metastases and primary tumors
in this model (P > .001). For three of these five metastases, matching
primary tumors from the same mouse were included in this analysis.
However, these metastases did not appear to have a closer similarity
to primary tumors in the same mouse than to either metastases or pri-
mary tumors in other mice (Figure 1, A and B). These observations
suggest that, in the MMTV-Neu transgenic model of breast cancer, ex-
pression profiles change very little either between metastases or between
metastases and primary tumors.
Within the MMTV-Wnt-1 transgenic model, two clusters were
detected (Figure 1, A and B). The metastases (with the exception
of one in Figure 1A) formed a distinct subcluster within one of these
two clusters, suggesting an insignificant change in expression patterns
in the transition from primary site to the lung. In accord, 83% of the
genes (322 of 388) that we previously reported to be differentially
expressed between primary tumors and hyperplastic mammary
glands from MMTV-Wnt-1 transgenic mice [14] were not differen-
tially expressed between metastases and primary tumors in this model.
For 7 of 10 metastases, matching primary tumors from the same
mouse were included in this analysis. However, metastases did not
have closer relations with their matching primary tumors than with
other metastases or other primary tumors (Figure 1, A and B). This
observation and the results from the MMTV-Neu model suggest that
expression profiles change very little either between metastases or be-
tween metastases and primary tumors when the same oncogene is tar-
geted to the same subset of mammary cells. However, analyses of a
larger number of metastases may reveal more subtle differences be-
tween metastases and/or between metastases and primary tumors within
each model, especially because our collection of metastases included
eight experimental metastases. Of note, experimental metastases in both
models did not segregate from the corresponding spontaneous metasta-
ses, suggesting that these experimental metastases probably did not af-
fect the clustering hierarchy of these arrays.
Pulmonary Metastases Preserve the Cellular Heterogeneity of
Primary Tumors in MMTV-Wnt-1 Transgenic Mice
It has not been demonstrated whether breast cancer metastases
preserve the cellular composition of their primary tumors, though
histologic features may be shared [6]. Using the permutation t test,
we found that pulmonary metastases from MMTV-Wnt-1 transgenic
mice expressed, at similar levels as their primary tumors, the epithe-
lial markers E-cadherin and β-catenin, the myoepithelial cell markers
calponin1 and 2, and a few markers that have been reported
[27,33,34] to be associated with stem and/or progenitor cells, such
as keratin 6, Sca1, CD44, CD24, integrin β1, and integrin α6 (data
not shown). Using immunohistochemical staining of paraffin sec-
tions of metastases from MMTV-Wnt-1 transgenic mice, we found
positive staining for the epithelial cell marker keratin 8, the myo-
epithelial cell marker α-SMA, and the potential progenitor cell marker
keratin 6 (Figure 2), as in primary tumors in the same transgenic
mice [18,26,28,30]. In addition, the ratio (0.98 ± 0.29) of epithelial
cells to myoepithelial cells in metastases was similar to that (1.20 ±
0.39) in primary tumors (P = .47). In contrast, only keratin 8 was
detected in metastases from MMTV-Neu transgenic mice (Figure 2),
as has been reported in their primary tumors [18,28,30]. These data
suggest that the cellular composition of primary tumors is preserved
in distant metastases.
Discussion
The expression profiling in two distinct mouse models of breast
cancer suggests that, at the expression level, individual metastases
from the same transgenic model are very similar to each other and
to their primary tumors (Figure 1). The high degree of similarity be-
tween metastases and primary tumors in the same model suggests
that changes in gene expression are probably small as primary tumors
in these models disseminate to distant locations, consistent with the
observation in humans that metastases closely recapitulate their cor-
responding primary tumors at the expression level [3–6]. Further
supporting the close similarity between metastases and primary tu-
mors, tumors arising from orthotopic transplantation of metastases
from MMTV-Wnt-1 transgenic mice did not have improved poten-
tial to metastasize (Podsypanina, unpublished data), as has been re-
ported for comparisons between cells isolated from metastatic sites
versus from primary sites [35]. However, our observations, as well
as the observations in human metastases, do not exclude the possi-
bility that, in the progression from primary tumors to metastases, ad-
ditional mutations occur, which promote metastasis but do not
significantly perturb global expression patterns [7,36,37].
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Figure 1. Comparison of gene expression between primary tumors and metastases in MMTV-Wnt-1 and MMTV-Neu transgenic models.
Average linkage hierarchical clustering analysis was performed on arrays of lung metastases (WntM or NeuM) and primary tumors
(WntT or NeuT) from MMTV-Wnt-1 and MMTV-Neu transgenic mice using 13,162 genes (all the genes on the array except those with
low quality across all samples) (A), or the 5704 genes that are not differentially expressed between primary tumors of MMTV-Wnt-1 and
MMTV-Neu transgenic mice (see Material and Methods section for more detail) (B). Paired primary tumors and lung metastases have
the same number. Experimental metastases are noted by an asterisk. These arrays were also analyzed by MDS using the 5704 genes
(C). The color of each tumor spot is coded as in A and B.
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The high similarity between individual metastases in each model
suggest that expression patterns vary only slightly among individual
metastases when their primary tumors are induced using the same on-
cogene in the same subset of mammary cells. This is interesting be-
cause differences in expression profiles [14,28,38], cell composition
[28], and susceptibility to mTOR inhibitors (Li, unpublished data)
are notable among primary tumors within the MMTV-Wnt-1 model.
These data also imply that secondary genetic alterations play only mi-
nor roles in the expression profiles when the Neu or Wnt oncogenic
pathway is the initiating event. Approximately 70% of the tumors ex-
hibit point mutations, small deletions, or insertions in the transgenic
Neu protooncogene in MMTV-Neu transgenic mice [39]; 50% of tu-
mors suffer an activating mutation in the H-Ras locus [40,41] in
MMTV-Wnt-1 transgenic mice. Because tumors in both models are
presumably clonal [16,39,40], a secondary mutation in either Ras or
the Neu transgene itself likely exists at the same frequency in its respec-
tive metastasis group, and has no significant influence on the expres-
sion profile of these metastases, as in the primary lesions [14,38].
Although highly similar to each other within the same model, ex-
pression patterns are quite different between MMTV-Neu–induced
metastases and those induced by MMTV-Wnt-1 (Figure 1A). This
difference may be attributed to several sources including the initiat-
ing oncogene and the cell of origin, both of which have an influence
on gene expression profiles of primary mammary tumors [9,28] (Bu
and Li, unpublished data). The addition of metastases from models
that share an initiating oncogenic pathway and/or a cell of origin may
reveal more similarities among metastases from different models.
However, even after genes that accounted for differences in primary
tumors between the MMTV-Neu and MMTV-Wnt-1 models were
excluded, large expression differences persisted between these two
sets of metastases (Figure 1, B and C ).
The high expression pattern similarity between individual metas-
tases in each model as well as the obvious expression dissimilarity in
metastases between the two models suggest that variations in the cancer-
initiating genetic alterations and possibly in the cell of cancer origin be-
tween patients may be partly responsible for the lack of close expression
similarity of distant metastases seen in the smaller number of breast can-
cer metastases that have previously been analyzed [3–6]. Analysis of
more human samples with similar sets of genetic alternations and/or
with similar histopathology features will help provide a more conclusive
answer to this possibility.
Multiple genetic mutations are usually required to cause human
malignancies [42,43]. The reported overall lack of similarity among
human breast metastases [3–6] might also be attributed to variations
in secondary oncogenic mutations, although secondary oncogenic mu-
tations do not seem to greatly influence the expression profiles of pri-
mary tumors in several models [14,28,38,44]. Furthermore, variation
of the genetic background in the human population may also be a
contributing factor to the differences in metastases between individual
patients. In addition, genomic instability is much higher in human
breast cancers than in these two and most other mouse models
[45,46]. Such genomic heterogeneity may also add to the more unique
expression profiles of human metastases. Analysis of metastatic tumors
from genomically unstable models such as p53-deficient mice [46]
Figure 2. Expression of keratin 6, α-SMA, and keratin 8 in lung metastases from MMTV-Wnt-1 and MMTV-Neu transgenic mice. Con-
secutive paraffin sections were stained by immunohistochemistry for the protein indicated at the top. The transgenic oncogenes are
indicated at the left. The inserts are four times the views of the boxed areas. Lung (L) and tumor mass (T) are indicated. Scale bars are
as shown.
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may help measure the contribution of genomic instability to gene ex-
pression profile differences.
Of note, most humans breast cancers arise from a few mutated
cells in a field of normal cells. However, the two transgenic models
used in this study and most other models of breast cancer were gen-
erated by expressing oncogenes in essentially all mammary epithelial
cells, and this widespread transgenic expression frequently impairs
the development of the mammary glands [46]. This abnormal envi-
ronment in transgenic models may have a different effect on the ex-
pression profiles of both primary tumors and metastases than the
usual environment of normal cells. Expression profiling of breast can-
cer models that initiate oncogenic mutations after the gland has de-
veloped and/or, in only a small number of cells [46–48], may
elucidate more realistically mechanisms underlying breast cancer de-
velopment and metastasis.
Interestingly, metastases in the MMTV-Wnt-1 transgenic model
were found to have high cellular heterogeneity (Figure 2), as do their
primary tumors [14,18,38]. Because these metastases are usually fo-
cal, it is likely that they had a clonal origin, as has been suggested for
metastases of several tissue types [49–52]. If so, these metastases may
arise from spread and colonization of cancer stem cells [35,53],
which appear to exist in this model [18,26,27]. Nevertheless, this
heterogeneity may also result from dissemination and colonization
of heterogeneous tumor cells that traveled as a group.
In conclusion, expression profiling of metastases and primary tu-
mors in two distinct mouse models of breast cancer suggests that pul-
monary metastases that share the same cancer-initiating oncogene
and cellular origin are similar in expression profiles to each other
and to their primary tumors, and that breast cancer metastases preserve
the cellular heterogeneity found in primary tumors.
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